SK-MEL-28 Cell Lysate: sc-2236

SK-MEL-28 cell lysate is derived from a human melanoma cell line, extensively utilized in research focused on melanocyte biology and melanoma. The lysate from SK-MEL-28 cells provides a crucial resource for studying the molecular mechanisms underlying melanoma progression and melanocyte function. Researchers use this lysate to investigate the expression and regulation of melanoma-specific antigens and the signaling pathways involved in melanogenesis and cellular proliferation. Key pathways frequently studied using this lysate include the MAPK/ERK pathway, which is pivotal in regulating cell growth and differentiation, and the PI3K/Akt pathway, important for survival signaling in melanoma cells. The lysate also aids in examining the impact of genetic alterations common in melanoma, such as mutations in the BRAF and NRAS genes, on cellular behavior. This application of SK-MEL-28 cell lysate in research settings allows for a deeper understanding of the basic science of melanoma. Such studies contribute to the foundational knowledge necessary for advancing scientific inquiry into the cellular and molecular characteristics of melanoma.

SK-MEL-28 Cell Lysate References:

1. Akt protein kinase enhances human telomerase activity through phosphorylation of telomerase reverse transcriptase subunit.  |  Kang, SS., et al. 1999. J Biol Chem. 274: 13085-90. PMID: 10224060
2. Role of oxidative stress and autoimmunity in onset and progression of vitiligo.  |  Laddha, NC., et al. 2014. Exp Dermatol. 23: 352-3. PMID: 24628992
3. A subtraction tolerization method of immunization allowed for Wilms′ tumor protein-1 (WT1) identification in melanoma and discovery of an antitumor peptide sequence.  |  Massaoka, MH., et al. 2014. J Immunol Methods. 414: 11-9. PMID: 25205401
4. Antiproliferative Effect of Rottlerin on Sk-Mel-28 Melanoma Cells.  |  Daveri, E., et al. 2015. Evid Based Complement Alternat Med. 2015: 545838. PMID: 26161122
5. Common BRAF(V600E)-directed pathway mediates widespread epigenetic silencing in colorectal cancer and melanoma.  |  Fang, M., et al. 2016. Proc Natl Acad Sci U S A. 113: 1250-5. PMID: 26787892
6. METCAM/MUC18 is a new early diagnostic biomarker for the malignant potential of prostate cancer: Validation with Western blot method, enzyme-linked immunosorbent assay and lateral flow immunoassay.  |  Pong, YH., et al. 2020. Cancer Biomark. 27: 377-387. PMID: 31958077
7. Detection of BRAF splicing variants in plasma-derived cell-free nucleic acids and extracellular vesicles of melanoma patients failing targeted therapy therapies.  |  Clark, ME., et al. 2020. Oncotarget. 11: 4016-4027. PMID: 33216826
8. Characterizing the Heterogeneity of Small Extracellular Vesicle Populations in Multiple Cancer Types via an Ultrasensitive Chip.  |  Wang, J., et al. 2021. ACS Sens. 6: 3182-3194. PMID: 34264628